CTOs on the Move

Omnichem USA

www.omnichemusa.com

 
Omnichem USA is a Elk Grove Village, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.omnichemusa.com
  • 1025 Charlela Ln Apt 303
    Elk Grove Village, IL USA 60007
  • Phone: 847.584.1956

Executives

Name Title Contact Details

Similar Companies

Emalex Biosciences

Developing new treatments for rare and orphan neurological conditions.

CEL-SCI

CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body`s natural defense system.

Advanced Biotech

Advanced Biotech is a Cobourg, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fate Therapeutics

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company`s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company`s immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.

Neoptx

Neoptx is a Hollywood, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.